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The role of soluble soluble urokinase-type plasminogen activator receptor (suPAR) as a biological marker for TB treatment eﬃcacy
on active pulmonary TB-AFB(+) patients was investigated. Twenty pulmonary TB-AFB(+) patients participated in a cohort study
for six months. The plasma suPAR level was measured using ELISA method before treatment, two months, four months and six
months after treatment. At the same time clinical parameters were also measured. Results indicated that all patients (n = 20)
showed highest plasma suPAR levels before treatment (median 12.775ng/mL) and signiﬁcantly decreased ( P = .0001 <.05,
R2 = .890) after 2 months (median 8.019ng/mL) and 4 months (median 5.771ng/mL) of treatment, respectively. However, only
slightly declined after 6 months therapy (median 5.009ng/mL), near control group level (median 4.772ng/mL). Interestingly, the
signiﬁcant reduced of suPAR level was parallel to treatment eﬃcacy and correlated with other clinical and laboratory parameters,
that is, decreasing of patients’ complaints, increasing of BMI (r =− 0.281), thoracic imaging improvement, sputum conversion,
decreasing of ESR (r = 0.577) and monocytes count (r = 0.536) with exception the width of lesion in thoracic imaging. In
conclusion, the suPAR level in could reﬂect the progress of TB therapy.
1.Background
The success in controlling Tuberculosis (TB) depends to a
great extent on the appropriate diagnosis, the right therapy,
treatment monitoring, and evaluation. Particularly concern-
ingthetreatment,thelongdurationoftherapymayadversely
aﬀect patient adherence to treatment and lead to failure of
the recommended treatment program. This urges a stringent
monitoring program that could show the progress of the
therapy earlier than normal therapy (min. 6 months). In the
last decade, several biological markers have been intensively
studied. Such markers could contribute, the improvement of
the quality of clinical trials; and therefore enable develop-
ment and validation of new therapeutic strategies.
One of the most intensively investigated biomarkers is
urokinase plasminogen activator receptor (uPAR), a cellular
receptor for serine protease urokinase plasminogen activator
(uPA). UPAR can be cleaved from the cell surface by a
number of protease, such as chymotrypsin, phospholipases
C, and uPA, to yield a soluble form of the receptor (suPAR)
that has intrinsic chemotactic properties [1, 2]. One study
has demonstrated elevated levels of suPAR in pulmonary
TB patient with higher suPAR levels in smear microscopy-
positive patients compared to smear-negative patients [3].
SuPAR is an inﬂammatory biomarker and thus not speciﬁc
for TB, but it is elevated by several infectious diseases and s
to reﬂect the severity of disease and may hence be used as a
prognostic tool. However, little is known about suPAR as a
prognostic marker in extrapulmonary TB [4].
Assuming that serum levels of suPAR reﬂect the progress
of the therapy, we investigated to access in prospective man-
ner whether serum levels of suPAR may be used to monitor2 Tuberculosis Research and Treatment
treatment of pulmonary TB-AFB(+) patients. In the present
study, the suPAR levels of TB pulmonary patients were
measured during-six-month therapy and compared with
other routine laboratory evaluation including Body Mass
Index (BMI), monocyte count, Erytrocyte Sedimentation
Rate, (ESR) and thorax imaging.
2.MaterialandMethods
2.1. Subjects. This study was conducted in Malang, where
the prevalence of new smears or cultures positive for TB was
107/100.000populationperyearbetween2008and2009.For
the study, 5 tuberculin skin test positive healthy community
controls and 20 positive, newly diagnosed pulmonary TB
with sputum AFB-(Acid-fast bacillu) positive patients were
enrolled. The inclusive criteria were patients with category I
of pulmonary TB who regularly took medication, were male
and female aged between 15–50 years, had a BMI (Body
Mass Index) >16, agreed to be the subject of the research,
and signed the informed consent. Exclusion criteria were
TB patients with other diseases (severe bacterial pneumonia,
HIV-AIDS, and heart disease, diabetes mellitus, heart and
kidney problems), extra pulmonary TB, pregnant patients,
and patients with psychiatric problems.
The patients received a six-month (26 weeks) directly
observed short course antituberculosis therapy as recom-
mended by the Indonesian National Tuberculosis Program
based on WHO TB guidelines.
2.2. TB Treatment. The drug regimen consisted of a ﬁxed
weight-dependent combination of INH (320–400mg/day),
rifampicin (480–600mg/day), ethambutol (800–1200mg/
day), and pyrazinamide (1000–1250mg/day) for the two-
month intensive phase, followed by rifampicin and INH for
the four-month continuation phase.
2.3. Routine Examination. Patient’s complaint was con-
ductedpriortotheclinicalandlaboratoryexamination,body
mass index, monocyte count, and Erythrocyte Sedimenta-
tionRate(ESR).Allweremeasuredaccordingtothestandard
procedure conducted in Indonesian Hospital [5].
2.4. ChestX-Ray Grading of Disease. Standard postero-an-
terior and lateral chest radiographs were taken prior to
therapy and were read by a pulmonologist. The grading
included the following categories: (i) minimal lesion, that
is, lesion width is less than area restricted to median line,
apex and front costae, solitaire lesion can be everywhere,
and there is no cavity found, (ii) moderate advanced, that
is, width of cavity is less than one lobe, and if there is cavity,
should be more than one lobe. (iii) far advance is width of
lesion that more than minimal and moderate lesion, if with
cavity, should not be more than 4cm.
2.5. Sampling Handling. S t u d ym a t e r i a l sw e r e3 m Lb l o o d
specimens obtained from new patients through aspiration
using injective needle before they started on antituberculosis
diagnosis at two, four, and six months after the initiation
of anti-TB drugs treatment based on WHO guideline
(2HRHZE/4H3R3) [5, 6]. Serum was separated by centrifu-
gation (6000xg) at 4◦C for 7min and aliquots of 500mL
stored at −80◦C.
2.6. Enzyme-Linked Immunoassaysorbant Assays. Serum
suPAR measurement was done in duplicate using com-
merciallyavailableELISAkitsaccordingtothemanufacture’s
protocol (suPARnostic, ViroGates A/S, Copenhagen, Den-
mark) [7]. Plate reading was conducted using a Biotech
micro plate reader set to 450nm, with the wavelength
correction set to 650nm. Concentrations of the respective
analyses were determined using SPSS version 3.4 software.
2.7. Statistical Analysis. All statistical analysis on suPAR was
carried out using SPSS software version and the statistical
programming language. Analyzed statistically, using longitu-
dinal model analysis, bivariate analysis, multivariate analysis
andlinearregression,theseanalysiswerecarriedoutwiththe
SAS 9.13 (SAS Institute, Cary, NC, USA) and SPSS 16 (SPSS
Inc, Chicago, IL) program.
The diﬀerence between the patients and the controls was
analyzed using one-way ANOVA. The association between
the immune parameters and the extent of disease was
assessed using the Mann Whitney U-test. A P-value of
P ≤ .05 was judged signiﬁcant.
2.8. Ethics. Written consent was obtained from all partici-
pants. The study was approved by the Ethics Committees,
Saiful Anwar Public Hospital, Brawijaya University.
3. Results
Twenty patients with active pulmonary TB were observed
during the six-month treatment. Characteristics of the
twenty patients are presented in Table 1.
The number of female pulmonary TB patients who
fulﬁlled the inclusion and exclusion criteria were (50%)
equal to the number of male patients (50%). Distribution
based on age in this study showed that TB patients were
mainly dominated by those aged between 19–30 years.
Measurement of suPAR concentration indicated that
there was a high level of suPAR in infected patients before
treatment(median12.775ng/mL),butsuPARlevelsdropped
signiﬁcantly (P = .0001 <. 05) after two months (median
8.019ng/mL) and four months (median 5.771ng/mL) of
therapy. However, at the sixth month of treatment, there was
only slightly decrease although signiﬁcant reached (median
5.009ng/mL) (Figure 1(a)). These were almost similar to the
healthy control group (median 4.772ng/mL).
With regard to clinical symptoms (Table 2), chronic
cough is the most common complaint, however, decreasing
of appetite, low grade fever, shortness of breath, haemoptoe,
and chest pain were also found. After the second and the
sixth month of treatment, some patients still complained
about coughing, shortness of breath, and chest pain. Con-
cerning sputum conversion, before treatment, all patients
(n = 20) had sputum-AFB(+) but after the two-monthTuberculosis Research and Treatment 3
Table 1: Clinical data of patients included in the study.
No Patients’ characteristics Frequency (n) Percentage (%)
1 Number of patients 20 100%
Male 10 50%
Female 10 50%
2 Age (years); age median = 30 years
19–30 12 60%
31–40 4 20%
41–50 4 20%
3
Width of lesion classiﬁcation
Minimal lesion 1 5%
Moderate advance lesion 7 35%
Far advance lesion 12 60%
4
Patients’ complaints
Chronic cough >3 weeks 20 100%
Decrease of appetite 15 75%
Low grade fever 10 50%
Shortness of breath 9 45%
Hemoptoe 9 45%
Chest pain 2 10%
Table 2: Comparison between medical records used to monitor TB theraphy progress in Indonesia, that is, patients complaints, BMI
(kg/m2), width of lesion, sputum AFB, erythrocyte sedimentation rate (mm/hour), monocyte count (cell/mm2), and soluble urokinase
plasminogen activator receptor during the 6-month therapy.
During anti-TB-drugs treatment
No. Medical records and level
of suPAR
Before
Treatment 2 months 4 months 6 months P-value
<.05
1
Patients’ Complaints
Chronic cough >3 weeks 20 (100%) 17 (85%) 5 (25%)
Decrease of appetite 15 (75%) 0 (0%) 0 (0%)
Low grade fever 10 (50%) 0 (0%) 0 (0%)
Shortness of breath 9 (45%) 5 (25%) 3 (15%)
Hemoptoe 9 (45%) 0 (0 %) 0(0 %)
Chest pain 2 (10 %) 1 (5 %) 1 (5 %)
2 BMI 18.28 ± 2.12 19.18 ± 2.31 20.36 ± 2.35 .0001
3
Width of lesion
classiﬁcation Thoracic Imaging n = 20 Thoracic Imaging n = 20
Minimal Lesion
Mod Advance Lesion
Far Advance Lesion
1( 5 % )
7 (35%)
12 (60%)
⎧
⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎩
Worsen : 0 (0%)
Unchange : 3 (15%)
Getting better : 17 (85%)
⎫
⎪ ⎪ ⎪ ⎬
⎪ ⎪ ⎪ ⎭
⎧
⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎩
Worsen : 1 (5%)
Unchange : 0 (0%)
Getting better : 19 (95%)
⎫
⎪ ⎪ ⎪ ⎬
⎪ ⎪ ⎪ ⎭
4 Sputum AFB(+) 20 (100%) 5 (25%) 0(0%)
5 ESR 84.15 ± 32.47 44.10 ± 29.97 19.30 ± 13.29 .0001
6 Monocytes Count 847.00 ± 244.52 662.00 ± 241.72 496.50 ± 129.67 0.0001
7 Level of suPAR 12.775 ± 3.940 8.019 ± 1.458 5.771 ±
0.796 5.009 ± 0.842 .00014 Tuberculosis Research and Treatment
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Figure 1: (a) Serum levels of soluble urokinase receptor (suPAR), (b) sedimentation rate of erythrocytes (ESR), (c) monocyte count (d)
Body Mass Index (BMI) in 20 TB patient before (0), during (2 and 4 months), and after (6 months) completion of anti-TB treatment.
Individual proﬁle (dotted line) and median (thick line) levels are shown.
treatment, ﬁfteen patients turned to be AFB(−), and by
the end of the six-month treatment, all patients showed
sputum conversion. During observation, most patients (19)
showed high level ESR, and it decreased signiﬁcantly (P-
value .0001 <. 05) from time to time during the six-month
treatment. ESR usually increased in active processes, but
normal ESR did not eliminate the diagnosis of TB [5]. In
this papaer, the highest median of ESR before treatment
was 84.2mm/hour, and then it dropped to 44.1mm/hour
after-two-month treatment. The lowest of the ESR level
was reached after six-month treatment (19.3mm/hour).
(Figure 1(b)) A signiﬁcant correlation between suPAR and
E S Rw a sf o u n d( P-value .0001 <. 05), with a quite strong
correlation coeﬃcient (r = 0.577).
The same trend was found on monocytes count. Before
treatment, monocytes count showed the highest concen-
tration (median 847cell/mm3) However, it dropped signif-
icantly (P = .0001 <. 05) after two (median 662cell/mm3)
and-six-month treatment (median 497cell/mm3) (Figure
1(c)). The decreasing suPAR level correlated signiﬁcantly
(r = 0.536) with the decreasing of monocytes count (P-
value .000 <. 05). We observed light monocytosis before
treatment, which went down in count during the treatment
period. In the normal condition, monocytes count in blood
was in the range of 0.3–0.8 ×103 cell/mm3.
Incontrast,BMIoftheTBpatientsrosegraduallybutsig-
niﬁcant (P = .012) after two (median 19.18kg/m2) and the
six-month of treatment. By the end of therapy, all patients’
weightreachedthehighestBMImean(median20.36kg/m2).
(Figure 1(d)). There was a signiﬁcant correlation (P-value
.012 <. 05) albeit weak (r =− 0.281) between the decrease
in suPAR with the increasing of BMI.
Finally, thoracic imaging of the patients who were
diagnosedtohaveactivepulmonaryTBshowedfaradvanced
lesions (n = 12), moderate advanced lesions (n = 7), and
minimal lesions (n = 1). However, there was no signiﬁcant
correlation between suPAR level with the width of lesions
on thoracic imaging of the TB patients before and after
treatment (Table 3).
4. Discussion
TB has remained in the third rank of infectious disease in
Indonesia for years. Lack of accurate method in monitoring
progress in TB therapy could be one of the causes of this
problem. The present study aimed to investigate the possible
use of suPAR as a biomarker in pulmonary TB-AFB(+)
patients, hence allow stratiﬁcation of treatment regimens
with possibly shortening of treatment in a majority of
patients that may not require a six-month treatment period
and intensiﬁed regimens in those with an increased risk for
poor response and relapse.
It is surprising to see in general that the range of suPAR
level in patients with active pulmonary TB (8.539ng/mL–
28.000ng/mL) was rather diﬀerent from African people
which ranged between 0.9ng/mL to 45ng/mL [2]. WhetherTuberculosis Research and Treatment 5
Table 3: Result of ANOVA Test.
No Width of lesion classiﬁcation Test Sig Sig < 0.05 Conclusion
1 Min lession, mod advance, far advance Anova test Sig F 0.901 Not Signiﬁcant
2 Min lession, mod advance T-test Sig t 0.61 Not Signiﬁcant
3 Min lession, far advance T-test Sig t 0.792 Not Signiﬁcant
4 Mod advance, far advance T-test Sig t 0.716 Not Signiﬁcant
these are genetically inﬂuenced, it needs further study. It was
found that suPAR level was elevated before treatment and
drastically dropped after two- and four- month therapy. A
decrease in suPAR after 8-month of Tb-treatment among
treatment responders was also found in the study of Eugen-
Olsen et al. [3]. Increased suPAR levels pretreatment may
be a result of mobilization of macrophage into the bronchi
and the increased immune activation and inﬂammation
caused by the active infection. Adherence and migration of
monocytes involves a functional interaction between uPAR
and integrins [8]. The reduction trend of suPAR during
six-month therapy was signiﬁcantly in accordance with
the decline in ESR, however, only signiﬁcantly correlated
with monocyte count. We only found light monocytosis
before the treatment which decreased in count from time
to time during anti-TB drugs treatment, the same is found
in previous ﬁnding [9] that showed that mild absolute
or relative monocytosis was found in 29% to 60% of TB
patients. Considering that suPAR attach on monocytes and
macrophage and play a role in cell migration [10], however,
seems that in this study, the level of suPAR did not reﬂect the
number of monocytosis. It is possible that release of suPAR
in the blood not necessary statistically comparable with the
process of monocytosis.
The drastic decrease of suPAR level in the ﬁrst two
months was weakly associated with raise of BMI. The raise
of appetite of TB patient might be due to decreasing of
TNF-alpha release [11]. These acts aﬀect the immune status
condition which sifted to Th2, resulting in the pressure on
Th1 or the existence of Th1 signal transduction resistance on
macrophage by tuberculosis bacilli and infection severity [8].
By the end of the initial phase treatment, there were ﬁve
patients who did not undergo sputum conversion yet, but at
the end of continuation phase, all the patients underwent
sputum conversion. Patient’s sputum conversion occurred
in 75%–85% cases after 2-month treatment and 96% cases
after six-month treatment [9]. Although the trend of the
drop of suPAR level and sputum conversion look similar,
nevertheless it is hard to correlate the sputum conversion
with the level of suPAR in the blood, since suPAR is not a
direct product of Mycobacterium.
Patients who have active pulmonary TB with AFB spu-
tum(+) were found mostly in pulmonary TB patients with
far advanced lesion, followed by moderate advanced lesion
then minimal lesion. Pulmonary lesion is considered to be
a key parameter used to diagnose and monitor the outcome
of the treatment. As the disease progresses its resulted in the
softening of caseosa necrosis, forming cavity containing a lot
of M. tuberculosis and bronchial wall erosion which then are
forced to come out through cough [12]. It is shown that in
thoracic imaging can occur in one to three ﬁrst month of
anti-TB drugs treatment, and this can be better or stable
in six months in 90% cases [9]. However, after 6 months
of treatments there was one patient who still underwent
destroyed pulmonary with wider atelectasis. In this study,
suPAR level among patients with far advanced lesion,
moderate advanced lesion, and minimal lesion did not diﬀer
signiﬁcantly. This is incontrastwith ﬁnding previous ﬁnding
[13] in which the suPAR level correlated signiﬁcantly with
width of lesion. To our knowledge, these could be due to the
use of diﬀerent method in measuring the lesion.
An interesting phenomenon was found in which the
suPAR level was much higher (28.000ng/mL) in one patient
withpulmonaryTBmiliarytype.PulmonaryTBmiliarytype
isknownasaseveretypeofpulmonaryTBduetohematogen
spread process that aﬀect all parts of the lung [10]. Whether
this one case reﬂects severity of the disease due to hematogen
spread still needs further proof in further study.
This wastheﬁrstresearchdone inIndonesia studying the
suPAR level during anti-TB drugs treatment. This research
was aimed at obtaining the applicable use of suPAR as a
complement to monitor treatment eﬃcacy. All 20 patients in
the current study responded clinically to the TB treatment.
The positive eﬀect of treatment was also reﬂected in decrease
in the inﬂammatory status as measured by suPAR levels.
Thus, we conclude that decreasing suPAR level may reﬂect
treatment eﬃcacy, but further studies involving TB patients
that do not respond to TB treatment is necessary to
determine if suPAR remains high for example, in TB-MDR
patients.
5. Conclusion
The decreasing of suPAR level in pulmonary TB patients
withactive AFB(+) wasa manifestation of treatmenteﬃcacy.
suPAR level elevated almost three times in TB patients before
treatment and drastically dropped after the ﬁrst two-month
treatment, followed by the gradual decrease until the end of
sixthmonthtreatmentthatwascomparabletosuPARlevelof
the healthy control. The reduction trend of suPAR level was
correlated to other clinical and laboratory parameters, that
is, disappearance of patients’ complaints, increasing of BMI,
declining of ESR, and fewer monocytes number. However,
suPAR concentration did not reﬂect the pulmonary lesion
width on thoracic imaging; hence, suPAR could not be used
as a sole biological marker to monitor the eﬃcacy of the
treatment.6 Tuberculosis Research and Treatment
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